MAD 0004J08
Alternative Names: MAbCo-19; MAD-0004J08Latest Information Update: 04 May 2022
At a glance
- Originator Toscana Life Sciences
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III COVID 2019 infections
Most Recent Events
- 20 Oct 2021 Toscana Life Sciences completes a phase I trials in COVID-2019 infections (In volunteers) in Italy (IM) (NCT04932850)
- 06 Jun 2021 Phase-II/III clinical trials in COVID-2019 infections in Italy (IM) (NCT04952805)
- 01 Mar 2021 Phase-I clinical trials in COVID-2019 infections (In volunteers) in Italy (IM) (NCT04932850)